Drug Profile
Research programme: inflammation therapeutics - Medisyn Technologies
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Medisyn Technologies
- Class
- Mechanism of Action 5-lipoxygenase inhibitors; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Inflammation in USA
- 15 Jul 2016 Early research in Inflammation in USA (unspecified route)